companiesCompany
Frontier Medicines
Chemoproteomics company with FMC-376, a KRAS G12C inhibitor that hits both the ON and OFF states of the protein, in phase 1/2.
FMC-376 covalently targets GTP-bound and GDP-bound KRAS G12C, designed to overcome adaptive RTK feedback that limits first-generation G12C drugs. PROSPER phase 1/2 (NCT06244771) recruiting; primary completion estimated October 2027.